SG11201700271RA - NOVEL ANTI-HUMAN Tie2 ANTIBODY - Google Patents

NOVEL ANTI-HUMAN Tie2 ANTIBODY

Info

Publication number: SG11201700271RA
Authority: SG; Singapore
Prior art keywords: novel anti; human tie2; tie2 antibody; antibody; human
Prior art date: 2014-07-15

Application number

SG11201700271RA

Inventor

Masazumi Kamohara

Shigenori Yagi

Yoshinori Ishii

Hiromi Nara

Original Assignee

Astellas Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-07-15

Filing date

2015-07-14

Publication date

2017-04-27

2015-07-14 Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc

2017-04-27 Publication of SG11201700271RA publication Critical patent/SG11201700271RA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues

SG11201700271RA 2014-07-15 2015-07-14 NOVEL ANTI-HUMAN Tie2 ANTIBODY SG11201700271RA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2014145135		2014-07-15
PCT/JP2015/070089 WO2016010014A1 (en)	2014-07-15	2015-07-14	NOVEL ANTI-HUMAN Tie2 ANTIBODY

Publications (1)

Publication Number	Publication Date
SG11201700271RA true SG11201700271RA (en)	2017-04-27

Family

ID=55078504

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201700271RA SG11201700271RA (en)	2014-07-15	2015-07-14	NOVEL ANTI-HUMAN Tie2 ANTIBODY

Country Status (18)

Country	Link
US (2)	US9683051B2 (en)
EP (1)	EP3170841A4 (en)
JP (2)	JP6699551B2 (en)
KR (1)	KR102455680B1 (en)
CN (1)	CN106687478B (en)
AR (1)	AR101202A1 (en)
AU (1)	AU2015290673B2 (en)
BR (1)	BR112017000689A2 (en)
CA (1)	CA2954754C (en)
IL (1)	IL249964B (en)
MA (1)	MA40182A (en)
MX (1)	MX2017000615A (en)
MY (1)	MY185811A (en)
PH (1)	PH12017500094A1 (en)
RU (1)	RU2702553C2 (en)
SG (1)	SG11201700271RA (en)
TW (1)	TWI685502B (en)
WO (1)	WO2016010014A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3102086A1 (en) *	2017-06-06	2018-12-13	Relinia, Inc.	Single-chain tnf receptor 2 agonist fusion proteins
CN111902426A (en) *	2018-03-05	2020-11-06	法国血液机构	Recombinant single-chain immunoglobulins
WO2019235856A1 (en) *	2018-06-07	2019-12-12	기초과학연구원	Antibody binding to tie2 and use thereof
EP3853249A4 (en) *	2018-09-21	2022-06-22	The University of North Carolina at Chapel Hill	Synthetic binding agents for limiting permeation through mucus
EP3960763A4 (en) *	2019-08-14	2022-12-28	Pharmabcine Inc.	Anti-tie2 antibody and use thereof
EP4061852A4 (en) *	2019-11-21	2024-03-13	Unity Biotechnology	Antibodies directed to tie-2 and methods of use
MX2022011752A (en) *	2020-03-24	2022-10-18	Genentech Inc	Tie2-binding agents and methods of use.
KR20220059924A (en) *	2020-11-03	2022-05-10	한국생명공학연구원	A Novel anti-Tie2 antibody or its antigen-binding fragments, and the use thereof
CA3217948A1 (en) *	2021-05-06	2022-11-10	Institute For Basic Science	Tie2 agonistic antibodies and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5879672A (en) *	1994-10-07	1999-03-09	Regeneron Pharmaceuticals, Inc.	Tie-2 ligand 1
AUPM379494A0 (en)	1994-02-10	1994-03-03	Ludwig Institute For Cancer Research	Immunointeractive molecules - ii
US6365154B1 (en)	1998-09-28	2002-04-02	Smithkline Beecham Corporation	Tie2 agonist antibodies
US6376653B1 (en) *	1998-09-28	2002-04-23	Smithkline Beecham Plc	Tie2 antagonist antibodies
NZ521540A (en) *	2000-04-11	2004-09-24	Genentech Inc	Multivalent antibodies and uses therefor
US7485297B2 (en)	2003-08-12	2009-02-03	Dyax Corp.	Method of inhibition of vascular development using an antibody
US8298532B2 (en) *	2004-01-16	2012-10-30	Regeneron Pharmaceuticals, Inc.	Fusion polypeptides capable of activating receptors
WO2009131239A1 (en) *	2008-04-25	2009-10-29	Kyowa Hakko Kirin Co Ltd	Stable polyvalent antibody
CA2818215C (en) *	2010-10-07	2015-07-21	Aerpio Therapeutics Inc.	Compositions and methods for treating ocular edema, neovascularization and related diseases
US9017670B2 (en) *	2011-08-19	2015-04-28	Regeneron Pharmaceuticals, Inc.	Anti-Tie2 antibodies and uses thereof
SG11201408530YA (en) *	2012-08-02	2015-03-30	Hoffmann La Roche	Method for producing monomeric and multimeric molecules and uses thereof

2015
- 2015-07-14 WO PCT/JP2015/070089 patent/WO2016010014A1/en active Application Filing
- 2015-07-14 SG SG11201700271RA patent/SG11201700271RA/en unknown
- 2015-07-14 MX MX2017000615A patent/MX2017000615A/en unknown
- 2015-07-14 AR ARP150102238A patent/AR101202A1/en unknown
- 2015-07-14 RU RU2017104642A patent/RU2702553C2/en active
- 2015-07-14 JP JP2016534433A patent/JP6699551B2/en active Active
- 2015-07-14 TW TW104122782A patent/TWI685502B/en active
- 2015-07-14 MA MA040182A patent/MA40182A/en unknown
- 2015-07-14 CA CA2954754A patent/CA2954754C/en active Active
- 2015-07-14 AU AU2015290673A patent/AU2015290673B2/en active Active
- 2015-07-14 MY MYPI2017700117A patent/MY185811A/en unknown
- 2015-07-14 EP EP15822476.6A patent/EP3170841A4/en active Pending
- 2015-07-14 BR BR112017000689-8A patent/BR112017000689A2/en active Search and Examination
- 2015-07-14 CN CN201580038358.6A patent/CN106687478B/en active Active
- 2015-07-14 KR KR1020177001003A patent/KR102455680B1/en active IP Right Grant
2016
- 2016-04-21 US US15/134,803 patent/US9683051B2/en active Active
2017
- 2017-01-08 IL IL249964A patent/IL249964B/en active IP Right Grant
- 2017-01-13 PH PH12017500094A patent/PH12017500094A1/en unknown
- 2017-05-03 US US15/585,374 patent/US9902782B2/en active Active
2020
- 2020-02-28 JP JP2020032764A patent/JP6860103B2/en active Active

Also Published As

Publication number	Publication date
IL249964A0 (en)	2017-03-30
CN106687478A (en)	2017-05-17
JPWO2016010014A1 (en)	2017-04-27
KR102455680B1 (en)	2022-10-17
RU2702553C2 (en)	2019-10-08
US20160222130A1 (en)	2016-08-04
TWI685502B (en)	2020-02-21
CA2954754A1 (en)	2016-01-21
EP3170841A4 (en)	2018-01-10
CA2954754C (en)	2023-01-17
RU2017104642A3 (en)	2019-03-07
JP6860103B2 (en)	2021-04-14
TW201617366A (en)	2016-05-16
KR20170029508A (en)	2017-03-15
PH12017500094A1 (en)	2017-05-22
JP6699551B2 (en)	2020-05-27
WO2016010014A1 (en)	2016-01-21
AU2015290673A1 (en)	2017-02-02
MX2017000615A (en)	2017-05-01
US20170253669A1 (en)	2017-09-07
US9683051B2 (en)	2017-06-20
US9902782B2 (en)	2018-02-27
RU2017104642A (en)	2018-08-15
BR112017000689A2 (en)	2018-01-23
CN106687478B (en)	2020-08-28
JP2020103302A (en)	2020-07-09
IL249964B (en)	2020-11-30
MA40182A (en)	2017-05-24
EP3170841A1 (en)	2017-05-24
AU2015290673B2 (en)	2020-10-29
AR101202A1 (en)	2016-11-30
MY185811A (en)	2021-06-10

Publication	Publication Date	Title
IL285287B1 (en)	2023-03-01	Antibodies to tigit
IL250583A0 (en)	2017-04-30	Anti-tigit antibodies
SG11201703403TA (en)	2017-05-30	Anti-tim-3 antibodies
SG11201703346PA (en)	2017-05-30	Anti-tim-3 antibodies
GB201411320D0 (en)	2014-08-06	Antibody construct
GB201411420D0 (en)	2014-08-13	Antibody constructs
IL252422B (en)	2018-06-28	Effector-deficient anti-cd32a antibodies
IL249964A0 (en)	2017-03-30	Novel anti-human tie2 antibody
IL250374B (en)	2021-04-29	Anti-ceramide antibodies
ZA201604640B (en)	2019-03-27	Novel anti-netrin-1 antibody
IL250404A0 (en)	2017-03-30	Novel anti-human igbeta antibody
RS59549B1 (en)	2019-12-31	Novel anti-presepsin antibody
GB201419089D0 (en)	2014-12-10	Anti-TIM-3 antibodies
GB201419092D0 (en)	2014-12-10	Anti-TIM-3 antibodies
GB201417614D0 (en)	2014-11-19	Antibodies
GB201414270D0 (en)	2014-09-24	Antibodies
GB201405775D0 (en)	2014-05-14	Antibodies
GB201401200D0 (en)	2014-03-12	Antibodies